Immuneering Corp (IMRX)

Immuneering Corp (IMRX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $255M; returns 1 day -2.1%, 1 week +3.9%, 1 year -33.7%.

Immuneering Corp is a clinical-stage oncology company specializing in 'Deep Cyclic Inhibition' of the MAPK (RAS/RAF/MEK) pathway, a critical signaling route that drives over 50% of human cancers.

Groups IMRX belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Healthcare
• Clinical Stage
• Cancer Therapeutics
• Pancreatic Cancer
• Drug Discovery
• Unmet Medical Needs
• Life Sciences

IMRX financial model: income statement, cash flow and balance sheet